Back to Search
Start Over
A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
- Source :
- BMC Urology
- Publication Year :
- 2017
- Publisher :
- Springer Science and Business Media LLC, 2017.
-
Abstract
- Background The aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with castrate-resistant prostate cancer (CRPC). Methods We retrospectively reviewed the medical records of 48 patients with metastatic CRPC who were treated with a biweekly regimen (intravenous docetaxel 40 mg/m2 on day 1 plus prednisolone 5 mg twice daily) between 2012 and 2015 at Samsung Medical Center (Seoul, Korea). Prior to the adoption of a biweekly regimen in Oct 2013, our institutional standard chemotherapy was docetaxel 75 mg/m2 every 3 weeks for patients with CRPC (n = 24). After Oct 2013, all chemotherapy-naïve patients with CRPC received a 40 mg/m2 biweekly regimen (n = 24). The primary end point was a PSA response, defined as a greater than 50% decline in PSA level from baseline. Results The baseline characteristics of the patients in the two treatment groups were similar. The most common cause of treatment discontinuation was disease progression, which was exhibited by 17 patients (71%) in the 3-weekly group and 20 (75%) in the biweekly group. PSA responses were observed in 12 (50%) and 11 (46%) patients in the 3-weekly and biweekly groups, respectively (p = 0.683). Time to treatment failure (TTTF, 4.5 vs 3.9 months) and time-to-progression (TTP, 5.0 vs 4.2 months) were not significantly different between the 3-weekly and biweekly groups. Conclusions Within the limitations of a retrospective study, the biweekly reduced dose docetaxel regimen was active and well-tolerated in Korean patients with metastatic CRPC.
- Subjects :
- Male
Oncology
medicine.medical_specialty
Urology
medicine.medical_treatment
Antineoplastic Agents
Docetaxel
urologic and male genital diseases
Biweekly
Drug Administration Schedule
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Asian People
Internal medicine
medicine
Clinical endpoint
Humans
030212 general & internal medicine
Neoplasm Metastasis
Aged
Retrospective Studies
Aged, 80 and over
Chemotherapy
business.industry
Retrospective cohort study
General Medicine
Middle Aged
medicine.disease
Discontinuation
Prostatic Neoplasms, Castration-Resistant
Regimen
Treatment Outcome
Reproductive Medicine
030220 oncology & carcinogenesis
Prednisolone
Feasibility Studies
Taxoids
Castrate-resistant prostate cancer
business
Research Article
medicine.drug
Subjects
Details
- ISSN :
- 14712490
- Volume :
- 17
- Database :
- OpenAIRE
- Journal :
- BMC Urology
- Accession number :
- edsair.doi.dedup.....cdc77025f8a6cd950c1291ef460ae019